2006
DOI: 10.1038/sj.gt.3302801
|View full text |Cite|
|
Sign up to set email alerts
|

T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery

Abstract: CCR5 is the chemokine co-receptor for R5-tropic human immunodeficiency virus type 1 (HIV-1) isolates most often associated with primary infection. We have developed an HIV-1 self-inactivating vector, CAD-R5, containing a CCR5 single-chain antibody (intrabody) gene, which when expressed in T-cell lines and primary CD4 + T cells disrupts CCR5 cell surface expression and provides protection from R5-tropic isolate exposure. Furthermore, CAD-R5 intrabody expression in primary CD4 + T cells supports significant grow… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
79
0
1

Year Published

2007
2007
2016
2016

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 72 publications
(81 citation statements)
references
References 79 publications
1
79
0
1
Order By: Relevance
“…To inhibit intracellular TLRs, which cannot be targeted by classical mAbs, antimalarial drugs and short DNA sequences are used, but they often lack sufficient specificity [12,16,17]. By contrast, ER-retained intrabodies do act specifically [18] and are capable of persistently blocking receptor functions if the intrabody gene is stably expressed upon retroviral or lentiviral virus infection [29,30]. Here, we developed an ER intrabody (αT9ib) for the specific knockdown of the intracellularly localized TLR9.…”
Section: Discussionmentioning
confidence: 99%
“…To inhibit intracellular TLRs, which cannot be targeted by classical mAbs, antimalarial drugs and short DNA sequences are used, but they often lack sufficient specificity [12,16,17]. By contrast, ER-retained intrabodies do act specifically [18] and are capable of persistently blocking receptor functions if the intrabody gene is stably expressed upon retroviral or lentiviral virus infection [29,30]. Here, we developed an ER intrabody (αT9ib) for the specific knockdown of the intracellularly localized TLR9.…”
Section: Discussionmentioning
confidence: 99%
“…Virus particles were generated as described elsewhere (Swan et al, 2006). SAEC and NCI-H661 cells were incubated with viral supernatants for 3 days in the presence of polybrene (4 μg/ml; Sigma).…”
Section: Lentivirus Production and Cell Transductionmentioning
confidence: 99%
“…Various intrabodies against HIV-1 proteins including Tat, Vif, Reverse Transcriptase and Integrase have been shown to inhibit virus replication in gene-modified cells in vitro (Goncalves et al, 2002;Kitamura et al, 1999;Levy-Mintz et al, 1996;Mhashilkar et al, 1995;Shaheen et al, 1996). Moreover, intrabodies against the viral co-receptors CXCR4 and CCR5 have been designed that retain these proteins in the ER (BouHamdan et al, 2001;Cordelier et al, 2004;Swan et al, 2006). Although these approaches efficiently inhibited HIV-1 replication in cell culture systems, intrabody techniques have not been further evaluated in vivo.…”
Section: Antiviral Proteinsmentioning
confidence: 99%